Pediatric Pediatric Vouchers

Pediatric Priority Review Vouchers

History

Kids v Cancer founder Nancy Goodman wrote the legislation that created the rare pediatric disease priority review voucher program after her son, Jacob, died of medulloblastoma at age 10. The drugs used to treat Jacob were all more than 40 years old, and they did not work. Nancy founded Kids v Cancer the day after Jacob died. Her goal was to change the landscape of pediatric drug development.

When the Creating Hope Act was introduced, the FDA had approved only one drug for childhood cancer since 1980, compared with 50 for adult cancers. Drug companies saw little profit in pediatric drugs. The Creating Hope’s answer was to reward pediatric approvals with something valuable to any drug company, at no cost to taxpayers: a priority review voucher, modeled on an existing voucher program for neglected tropical diseases.

Representatives Michael McCaul (R-TX) and G.K. Butterfield (D-NC) introduced the Creating Hope Act on September 23, 2011. Senators Bob Casey (D-PA) and Scott Brown (R-MA) introduced the Senate companion. The Creating Hope Act was based on the Tropical Disease PRV program that had been passed into law five years earlier. That program had been viewed as unsuccessful: it had not generated any new tropical disease drugs. Nancy proposed amendments to this law:

— to make the vouchers infinitely transferable

— to provide that a pediatric drug can still be eligible for a voucher if it is approved in another country,

— to shorten notice companies provide FDA when planning planning to exercise a voucher from 365 days to 90 days

— to provide rights to companies to claw back their vouchers and not exercise the vouchers during the notice period

— the creation of a designation program to give notice to companies seeking to earn a voucher that their drug, if approved, was eligible for a voucher

Congress enacted the bill as Section 908 of the Food and Drug Administration Safety and Innovation Act, which President Obama signed on July 9, 2012. The law also made vouchers freely transferable. It allowed sponsors to seek designation early in development, and it closed a loophole that had let companies earn vouchers for products already sold abroad.

Kids v Cancer mobilized kids to lead its grassroots campaign: children with cancer, survivors, siblings and other young advocates.

Congress extended the program in 2016 and again in 2020. The National Organization for Rare Disorders later reported that of the 39 rare pediatric diseases with vouchers, only 3 had an FDA-approved treatment before the program existed.

How vouchers work

The program rewards companies that win FDA approval of new drugs and biologics for rare diseases that primarily affect children. With each qualifying approval, FDA awards the sponsor a voucher. The voucher entitles the holder to priority review of a later, unrelated marketing application: FDA aims to act within six months instead of the standard ten. Vouchers can be sold, and they have sold for more than $100 million. [See our tracker of voucher sales and prices →]

Why vouchers matter for children

Most childhood diseases, including childhood cancers, are rare. A drug developed only for children often cannot earn back its development costs from sales. The voucher gives a pediatric approval value that does not depend on the size of the pediatric market. A company can use the voucher to speed review of a larger product, or sell it to a company that will.

Pediatric cancer drugs that have earned vouchers include dinutuximab (Unituxin) for high-risk neuroblastoma in 2015, tovorafenib (Ojemda) for pediatric low-grade glioma, and dordaviprone (Modeyso) for H3 K27M-mutant diffuse midline glioma. For the current number of vouchers FDA has awarded, see our tracker below.

Which approvals qualify

A rare pediatric disease is a serious or life-threatening disease whose serious or life-threatening manifestations primarily affect people from birth to 18 years old. It must also qualify as a rare disease, generally meaning it affects fewer than 200,000 people in the United States.

To earn a voucher, the approved application must:

  • be for the prevention or treatment of a rare pediatric disease;

  • contain no active ingredient FDA has previously approved;

  • rely on clinical data from studies in pediatric populations, at doses intended for those populations; and

  • not seek approval for an adult indication in the same application.

Sponsors can ask FDA to designate a product as a drug for a rare pediatric disease during development. Designation is optional. The voucher depends on meeting the criteria at approval.

Whoever redeems a voucher pays a priority review user fee, which FDA sets each year. The fee is due when the application redeeming the voucher is submitted.

Lapse and reauthorization

FDA’s authority to designate new products expired on December 20, 2024, which left developers without a clear path to a voucher. On February 3, 2026, the program was reauthorized by the Mikaela Naylon Give Kids a Chance Act, enacted as part of the Consolidated Appropriations Act, 2026 (Pub. L. No. 119-75). FDA may now award vouchers for qualifying approvals through September 30, 2029. The law also directs the Government Accountability Office to study the program’s effectiveness, including:

  • which products earned vouchers;

  • whether those approvals met unmet medical needs;

  • how vouchers were sold and used; and

  • whether the program changed development and investment decisions.

IF YOU WANT TO LOOK UP THE LATEST VOUCHERS, CLICK HERE!